title: Laboratory protocol for exercise asthma to evaluate salbutamol given by two devices.
abstract: OBJECTIVE
  As new delivery devices and formulations are being introduced for drugs given by inhalation, there is a need to evaluate their equivalence with old preparations. One way to do this is to investigate their equivalence in protecting from exercise-induced asthma (EIA).
  
  
  METHODS
  We used a protocol for EIA to compare the protective effect of salbutamol delivered by the pressurised metered dose inhaler (pMDI) and the new Diskus dry powder device. Twenty-seven asthmatic subjects with moderately severe EIA completed an exercise test on four separate days at two study centers. Exercise was performed by cycling for 8 min while inhaling dry air (0% RH, 20-24 degrees C). The target workload in W was predicted as (53.76 x predicted FEV1) - 11.07 and 95% of this target was achieved at 4 min of exercise. This target was chosen in order to achieve ventilation between 50 and 60% of predicted maximum in the last 4 min.
  
  
  RESULTS
  There was no significant difference in the workload, ventilation, or heart rate achieved on the study days. The severity of EIA was measured as the % fall in FEV1. EIA severity was similar on the placebo and control day and the coefficient of variation was 19.4%. The mean +/- SD % fall on the control, placebo, salbutamol by Diskus, and pMDI were 42.0% +/- 15, 39.4% +/-17.6, 13.4% +/- 13.2, and 8.5% +/- 13.8, respectively. Salbutamol significantly inhibited the % fall in FEV1 after exercise, and there was no difference between the preparations.
  
  
  CONCLUSIONS
  The protocol described here is suitable for evaluating equivalence of salbutamol preparations in protecting against EIA and could be used to evaluate the protective effect of other medications.
authors.affiliation: Department of Respiratory Medicine, Page Chest Pavilion, Royal Prince Alfred Hospital, Missenden Road, Camperdown NSW 2050 Australia. sandya@mail.med.usyd.edu.au
authors.forename: S D
authors.initials: SD
authors.lastname: Anderson
authors.forename: S
authors.initials: S
authors.lastname: Lambert
authors.forename: J D
authors.initials: JD
authors.lastname: Brannan
authors.forename: R J
authors.initials: RJ
authors.lastname: Wood
authors.forename: H
authors.initials: H
authors.lastname: Koskela
authors.forename: A R
authors.initials: AR
authors.lastname: Morton
authors.forename: K D
authors.initials: KD
authors.lastname: Fitch
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D000420:Albuterol / Q000008:administration & dosage / Q000494:pharmacology*; D001250:Asthma, Exercise-Induced / Q000517:prevention & control*; D001985:Bronchial Provocation Tests / Q000379:methods*; D004311:Double-Blind Method; D005260:Female; D006339:Heart Rate; D006801:Humans; D008297:Male; D009330:Nebulizers and Vaporizers; D012119:Respiration; D013810:Therapeutic Equivalency; D016896:Treatment Outcome
chemical_list: D000420:Albuterol